Welcome to our dedicated page for LENZ Therapeutics SEC filings (Ticker: LENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENZ Therapeutics, Inc. filings document the company’s transition from ophthalmic product development to commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults. Form 8-K disclosures cover financial results, FDA approval and U.S. availability of VIZZ, product launch updates, safety-related communications, and capital-raising activity under an at-the-market sales agreement.
The company’s proxy and governance materials address shareholder voting matters, executive and board governance, material agreements, capital-structure disclosure, and operating and financial results. The filing record also captures regulatory and commercial disclosures tied to VIZZ, including product approval, launch-stage operations, financing transactions, and risk-related information relevant to a pharmaceutical company commercializing an ophthalmic prescription product.
LENZ Therapeutics disclosed an insider purchase. A Director bought 10,500 shares of common stock on 11/07/2025 at a weighted-average price of $22.7884. After the transaction, the Director beneficially owns 10,500 shares directly and 620,599 shares indirectly through a trust. The indirect holdings include 95,034 shares transferred to the McCollum Living Trust on June 6, 2024.
LENZ Therapeutics (LENZ) reported an insider purchase by its Chief Financial Officer, Daniel R. Chevallard. On 11/07/2025, he bought common stock in two open‑market transactions coded “P”: 20 shares at $22.71 and 2,178 shares at $22.7561. Following these trades, he directly owns 5,386 shares.
LENZ Therapeutics (LENZ) reported Q3 2025 results and highlighted FDA approval of VIZZ. The company recorded $12.5 million in license revenue in the quarter and $17.5 million year-to-date. Operating expenses rose with commercialization activities, led by selling, general and administrative of $27.6 million and research and development of $3.8 million, resulting in a net loss of $16.7 million (basic and diluted loss per share of $0.59).
LENZ ended September 30, 2025 with $202.2 million in cash, cash equivalents, and marketable securities and reported 28,540,519 weighted‑average shares outstanding for the quarter. The company sold 920,500 shares via its at‑the‑market program during the nine months ended September 30, 2025 for $26.1 million in net proceeds, and subsequently sold 2,698,134 shares in October at a weighted‑average price of $45.79. On July 31, 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults.
LENZ Therapeutics, Inc. furnished a Form 8-K announcing its financial results for the quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, and incorporated by reference.
The Item 2.02 disclosure and the press release are furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act. Exhibits include the press release (99.1) and the cover page interactive data file (104).
Lenz Therapeutics, Inc. reported that it sold 1,748,634 shares of common stock on October 7, 2025 at a purchase price of $45.75 per share in a block trade to a single investor. The transaction generated gross proceeds of approximately $80,000,000 for the company. The sale was executed under the company’s existing “at the market” Sales Agreement with TD Securities (USA) LLC, dated April 4, 2025, and was completed pursuant to the terms of that agreement.
Versant entities reported insider sales of 224,974 shares of LENZ Therapeutics, Inc. (LENZ) on 09/30/2025. The Form 4 shows multiple sales by related reporting persons (including Versant Venture Capital VI, L.P. and affiliated Versant GP and Vantage entities) executed at weighted-average prices in ranges of $45.00–$45.99, $46.00–$46.99, and $47.00–$47.02. Post-transaction beneficial ownership amounts are disclosed for direct and indirect holdings, with several Versant entities retaining substantial positions (for example, 1,133,842 shares reported as directly owned by one entity and 842,162 shares indirectly held by another). The filing is signed by Max Eisenberg for the Versant reporting entities on 10/02/2025. The footnotes explain that reported prices are weighted averages from multiple transactions and identify the chain of general partners that may share voting and investment power over the disclosed holdings.
LENZ Therapeutics announced that VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved in the United States for treating presbyopia in adults, is now available. This medicine is intended to help adults with age-related difficulty focusing on near objects.
LENZ has begun distributing professional product samples nationwide through its sales force to optometrists and ophthalmologists so eye-care professionals can evaluate and introduce VIZZ to patients. Commercial product shipments to consumers will begin in October through an ePharmacy partner and are expected to expand to broad retail pharmacy availability by mid‑Q4 2025.
Versant entities reported multiple sales of LENZ Therapeutics common stock on 09/18/2025. The Form 4 shows a series of dispositions at weighted-average prices of $41.5908 (sales between $41.25 and $42.24) and $43.0038 (sales between $42.25 and $43.24), plus small sales at $43.30.
Reported transactions include direct and indirect sales: for example, 49,479 and 40,907 shares sold directly and 24,370 and 20,148 shares sold indirectly across the two weighted-average-price groups. The filings list 1,224,718; 1,183,811; and related post-transaction beneficial ownership totals for the reporting entities, and note 842,162 shares held indirectly by Versant Vantage II, L.P.
Versant investment funds disclosed holdings and recent sales of LENZ Therapeutics common stock. Multiple Versant entities report beneficial ownership stakes of 1,183,543 shares (4.1%) for Versant VI, 842,162 shares (3.0%) for Versant Vantage II, and 926,691 shares (3.2%) for Versant VII (the latter includes 70,534 shares issuable on a warrant). The filing lists a series of open-market dispositions in August and September 2025 by Versant VI and Versant VII, including sales on August 22, August 25, August 26 and September 18, 2025 that generated aggregate proceeds in the low millions on each date (examples: Versant VI sold 90,654 shares on September 18, 2025 for approximately $3,828,631.71; Versant VII sold 44,650 shares that same date for approximately $1,885,723.80). The Amendment updates Item 5 of the prior Schedule 13D filings and states that only the amended items are changed, leaving prior disclosures unchanged.
Versant entities reported multiple sales of LENZ Therapeutics common stock on August 22, 25 and 26, 2025. The filing lists a series of non-derivative sales totaling 188,094 shares across those dates at weighted-average prices in ranges between $38.50 and $40.8819 per share. The reporting parties include Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P., and related general partner and GP-GP entities. Footnotes state that certain holdings are held indirectly by VVC VI, VVC VII and VV II, and that the reporting entities may be deemed to share voting, investment and dispositive power over those shares. The Form 4 is signed by Max Eisenberg as Chief Operating Officer for the reporting entities.